Apimeds Pharmaceuticals UsAPUS -2.04%14 Pretax Margin % is % as of Mar. 2026. GuruFocus rates APUS with a GF Score™ of 14/100. The stock has 3 warning signs investors should review. Among 961 Drug Manufacturers companies, Apimeds Pharmaceuticals Us ranks worse than 104058.17% on this metric.
The historical rank and industry rank for Apimeds Pharmaceuticals Us's Pretax Margin % or its related term are showing as below:
APUS's Pretax Margin % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 7.28 * Ranked among companies with meaningful Pretax Margin % only.
Apimeds Pharmaceuticals Us (AMEX:APUS) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Apimeds Pharmaceuticals Us Pretax Margin % Related Terms
Apimeds Pharmaceuticals Us Pretax Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
APUS vs KAYS, BIOE, BFRI: Pretax Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Apimeds Pharmaceuticals Us's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Apimeds Pharmaceuticals Us Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Apimeds Pharmaceuticals Us's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Apimeds Pharmaceuticals Us's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Apimeds Pharmaceuticals Us (APUS) has a Pretax Margin % of % as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Apimeds Pharmaceuticals Us and its competitors. According to the industry distribution chart, Apimeds Pharmaceuticals Us ranks #999999 out of 961 companies in the Drug Manufacturers industry.
Is Apimeds Pharmaceuticals Us' Pretax Margin % too high?
Apimeds Pharmaceuticals Us' current Pretax Margin % is %. Based on the distribution chart, Apimeds Pharmaceuticals Us ranks #999999 out of 961 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Apimeds Pharmaceuticals Us has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Apimeds Pharmaceuticals Us' Pretax Margin % compare to KAYS and BIOE?
According to the Drug Manufacturers industry distribution chart, Apimeds Pharmaceuticals Us ranks #999999 out of 961 companies for Pretax Margin %. This places Apimeds Pharmaceuticals Us in the lower half of its industry. The industry median Pretax Margin % is 7.28. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.28, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Apimeds Pharmaceuticals Us and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Apimeds Pharmaceuticals Us's current Pretax Margin % is %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apimeds Pharmaceuticals Us stock overvalued right now?
Apimeds Pharmaceuticals Us (APUS) has a current Pretax Margin % of %. The current Pretax Margin % is %. Apimeds Pharmaceuticals Us' overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Apimeds Pharmaceuticals Us (APUS), the current Pretax Margin % is % as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Apimeds Pharmaceuticals Us Inc is a development-stage biopharmaceutical company. The Company operates its biopharmaceutical business. Its primary focus is the clinical development of Apitox, a purified honeybee venom-based drug candidate being evaluated for the treatment of pain and inflammation associated with knee osteoarthritis. The Company operates in two segments: the biopharmaceutical segment, which is focused on the clinical development of Apitox through Lokahi, and the digital asset operations segment, which encompasses the holding, sale, and advancement of the MindWaveDAO blockchain and related digital assets through MindWave.
14GF Score
Get the complete analysis for APUS
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
APUS has been successfully added to your 
